Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BLLZ...added to my position.....
Accumulated some more BLLZ in the last couple of weeks or so. Appears to becoming a little more difficult to acquire large blocks of shares at the one cent level, so that might be an encouraging sign.
The market interest/environment for this stock could see a positive change if the CEO does follow through on a Nevada reinstatement and updated OTC filings.
Some of my concerns about the filings/disclosures......
I think a lot of investors (myself included) are probably waiting for additional weakness in the share price before any entry or additional accumulation.
I have already been burnt once before by an ASKH periodic filing (2014 10-K) that turned out to inaccurate. Management completely failed to disclose its October 2014 floorless convertible in that particular filing, and then to make matters even worse it did not disclose that debt until about one year later. Needless to say, that kind of managerial incompetence is completely unacceptable.
It would be somewhat tempting to pick up ASKH shares at sub-penny prices if we could be absolutely certain that the October 2014 debt is the only floorless convertible that ASKH has on its books, and we could be certain that management will not engage in any further financing of this nature.
What I want to see is full disclosure in an 8-K or the next periodic filing on a couple of items that are of concern to me......
1) The $22.5K debt owed to Artfield Investments is still sitting on the balance sheet and it is convertible into shares. It has now been more than 2 years, and ASKH still has not provided any details at all on the conversion terms of that debt.
2) The CEO should set exact repayment terms on the related party debt that the company owes to him, so there will be no unpleasant surprises if/when he decides to convert that debt into shares. The fact that the CEO loaned the company a large chunk of money, but decided not to pay off that toxic debt has me a little concerned that the CEO might decide to convert his debt at an extremely low price.
SEC's approach to suspension/revocation needs improvement......
Unfortunately, the SEC pretty much has a "We can do whatever we want, whenever we want" approach to stocks that are not trading on the big boards. That kind of attitude poses a great deal of danger for many of the stocks we are interested in, and also furthers the SEC's ultimate goal of ending all (or at least severely curtailing the number of) reverse mergers in the US market.
Quite a few years ago I recall one of the SEC's "underlings" did an interview regarding all the controversy surrounding the Chinese stocks and the problems with the audits. That person made a statement which made it pretty clear that the SEC has a deep-seated dislike for the whole idea of reverse mergers. Basically the SEC wants to force any company that wants to go public to take on an underwriter and go through an "IPO process", regardless of whether you actually needed or wanted to have an underwriter involved with company. It wouldn't be easy for the SEC to actually implement this policy because it would receive severe backlash from lawyers, companies, etc, but if it did get implemented it would have a pretty negative impact on the reverse merger and direct registration markets.
The current approach the SEC takes toward suspension/revocation of delinquent or dark tickers really does a disservice to the average retail investor. There is simply too much inconsistency and not enough adequate public disclosure of its policy and actions. It needs an overhaul.
There really is no excuse why the SEC can not conduct its suspension/revocation process completely in the open. Every investor should be given the opportunity (in real time) to know when the SEC has contacted a potential suspension/revocation target, exactly what the SEC is requesting/demanding of the company, any exact timelines for response/punishment the SEC has made, and any response the SEC has received from the company.
By not making full disclosure of all of this, the SEC potentially allows insiders/friends/associates of the company an opportunity to make a buy/sell decision while the average retail investor sits there in the dark unaware of what is going on behind the scenes. For an organization that is supposedly looking out for the "little guy", this is an completely unacceptable way to handle the situation.
Many of the opinions/statements I made in the post below on another board still stand today.....
MAVT(.0061)...picked up a position.....
PGUZ(.002)...worth monitoring for possible changes....
An extremely high-risk investment, but I'm still holding my position in PGUZ in case there is an upcoming change/addition to management or some other catalyst that might cause movement in the stock.
The CEO (Daniel Kesonen) passed away on August 4 from cancer (and I believe there was a stroke at some point, based on a social media posting I have seen). I would assume his health had been declining for much of 2017.
Kesonen had mentioned to other shareholders last year about the possibility of issuing an update/news around August/September of 2016. Kesonen seemed to make it clear that PGUZ was still actively involved in the areas of mold treatment and cardiac diagnostics. Obviously that update did not occur, but I did find it somewhat interesting that websites apparently closely associated with PGUZ's technologies had unusual update activity during 2016. For example, websites connected to PGUZ's MoldGuardian product had new images/pictures uploaded to those sites right around the time frame of June-August 2016.
PGUZ's annual filing for Nevada is due in about 2 months. Olof Hildebrand (who I believe is an active lawyer in Europe/Sweden) is the only other officer listed. So it should be interesting to see what happens when the Nevada deadline arrives. I am crossing my fingers that there were contingency plans put in place prior to Kesonen's death, and that Hildebrand or one of Kesonen's business associates will keep the company active in some form (either as a current operating company or a shell vehicle for a reverse merger).
http://www.legacy.com/obituaries/dignitymemorial/obituary.aspx?n=daniel-kesonen&pid=186304034
GSAC(.0033)...Mastix issued cannabis-related patent allowance.....
TVER(.0021)...purchased some shares....
It has been over 4 months since the management change at TVER. Investor interest in the stock has pretty much dropped off after that initial burst of interest/activity. I'm gambling/guessing this might be a good time to buy some shares.
I picked up some shares at .003 recently. This is probably at the upper limit of what I am willing to pay because there is suspension/revocation risk, and there was some unresolved debt still on the balance sheet at the time of its last filing in 2014.
All things considered, I figure the risk/reward at this level seems relatively reasonable.
MRDH(.0021)...might be worth monitoring.....
MRDH is an extremely high-risk investment, but it might be worth placing on a watch list just in case something is happening on the corporate level or in case the stock gets another push sometime this year. The stock has had some impressive/wicked swings in price over the last couple of years or so, and it would not surprise me if that type of movement occurs again.
A few weeks ago the OTC profile share structure was updated on both MRDH and its sister stock (ICCO). I think it has been 6+ years since the last time the structures were updated. MRDH's new number reflects about a 50M increase. I can't recall what ICCO's previous number was, but I think the new number is a similiar or slightly higher increase than MRDH.
Something that has caused my eyebrow a raise a little bit recently is the fact that during the month of June ICCO placed two job postings. One was for a sales representative and another was a general posting seeking business partners and distributorships. This was extremely unusual because in all the years that I have followed or owned MRDH/ICCO I have never seen the companies post any job listing on any mainstream job placement website.
Also, I am not 100% certain about this but a couple of months or so ago I remember checking on the California business status of ICCO and the database showed it as being "inactive". It now shows up as being "active".
MRDH's primary business activity involves managing a multi-state Accountable Care Organization, with the majority of its patients in Florida and California. The Centers for Medicare & Medicaid Services(CMS) releases ACO perfomance data for the previous year around August/September each year. The performance of each ACO is measured against its individual benchmark. While this data does not reflect the actual financial performance (revenue, net income, or net loss) of each ACO management company, it can give you some glimpse of how effective or ineffective the ACO has been.
I have had difficulty accessing the CMS database recently, so the numbers below are as best as I can remember when I checked on Meridian Health Systems ACO last year. The performance of MRDH's ACO has shown significant improvement over the last 3 years. It has gone from a negative $14M (2013), to a negative $5M (2014), to a positive $250K (2015). I don't recall what the total amount of medicare-related services that MRDH's ACO provided during 2015, but the number in 2014 was over $170M.
http://mhsaco.us/
CLCL...reply to private message....
To the person who sent me a private message regarding my current thoughts on CLCL......
I still own my position in CLCL, have added to that position, and might continue to add shares. But, having said that, I think the risk level of the stock has increased considerably since my last post.
Let me preface this by saying that I'm not aware of whatever (if anything) is happening behind-the-scenes on a corporate/management level, and whether those things (if any) would make those of us retail investors much more comfortable with our current positions in this stock. Hopefully my concerns will turn out to be overblown, but until we see some concrete positive corporate activity it is probably prudent to be at least somewhat alarmed/concerned with what is going on.
I'm not at all pleased with a number/variety of things regarding management (CEO Norm Kaplan) here. It is entirely possible that Kaplan never had any real intentions of updating the corporate and product website(s) as he had mentioned in his email last year. Kaplan allowed the registrations to the sites to expire and the corporate website was scooped up by one of those website "vulture" firms. If his intention going forward is to operate the company without any significant website presence, I think that is a huge strategic blunder on his part.
One of my concerns at the moment is whether Kaplan is truly committed to advancing the company and keeping the stock active/alive. The SEC's "pre-emptive strike" policy (in which the SEC seeks to suspend/revoke non-filing stocks) poses a potential serious threat to CLCL. The absence of an informational, fully-updated corporate website certainly doesn't help the situation.
If the SEC does contact CLCL and makes its usual requests/demands, I just don't know if Kaplan would have the ability or willingness to actually satisfy the SEC's demands. I don't know if Kaplan fully understands/appreciates the danger he is placing the stock in by not taking at least some minimal actions/efforts that might help avoid having the SEC suspend/revoke CLCL's registration, for example: get the OTC profile fully updated, some filings, etc., etc.
The upside potential from these price levels could be substantial, but there is also a very real possibility that any continued/additional investment in CLCL could end up being just a complete waste of time/money.
BLLZ(.015)...added more to my position.....
Picked up another large block of shares at .01 a couple of weeks ago.
BLLZ(.01)..March 30 PR, accumulated position.....
Finished accumulating a position in the sub-penny to penny level over the last few weeks. Was pretty difficult to purchase any sizable blocks under the .006 level, so decided to pick up some larger blocks around this one-cent area. Looks like the stock could be capable of some explosive swings/moves in the share price under the right situations.
Thought it might be wise to be pre-positioned ahead of a possible reinstatement, OTC profile/filings update, and increased corporate actions (including divesture/acquisition activity). BLLZ also is a bit interesting at this point because it is a lesser-known play in the cyber security area of the market.
The March 30 press release.....
VODG(.135)...corporate activity expected to increase.....
I'm expecting to see a significant increase in corporate activity and a more robust approach to investor relations at VODG following a successful closing on the proposed $1.7 million financing. As per the recent press release and 8-K filing, the company should regain SEC compliance and there will be changes/additions to management and the Board of Directors.
The person/entity that is providing the $1.7M financing is prepared (if necessary) to loan/invest an additional $6.6M in VODG. But with a new CFO expected to officially come on board, I wouldn't be surprised if VODG starts attracting additional financing(s) from third parties.
It appears the proposed activity/transactions outlined in the release/filing have been under development for at least 8+ months, since the VODG CEO registered the website for the company's new subsidiary (Halo Cell Sciences) back in August 2016. The website came online last week with the "Website Coming Soon" sign.....
http://www.halocellsciences.com/
VODG...upcoming major corporate developments.....
GSAC(.0033)...cannabis IP, contract manufacturing......
Added a few more shares to my position. GSAC continues to be a largely under-followed sub-penny play with connections to the cannabis sector. GSAC's involvement in the cannabis sector comes in the form of its contract manufacturing business (gum, lozenges, confectionery products, etc), pending patents on its manufacturing processes, and its own proprietary brands of CBD-infused products.
The stock is trading at a pretty steep discount to the 7 cent share price it was trading at when it acquired Mastix Medica in 2014.
PGUZ(.0042)...Amgen, Cannabis mold prevention, etc.....
Accumulated a position in PGUZ (mostly at .004/shr) over the last few months. Definitely a high-risk investment for a number/variety of reasons, but the risk/reward around this price level looks intriguing. There has been some interesting activity on websites during 2016 that may have direct/indirect connections to products or technologies that have been associated with PGUZ.
One thing I would like the CEO to do is provide a very clear/detailed picture of PGUZ's current relationship/connection to the primary product/technology areas it is (or has been) involved with (anti-fungal products and the cardiac screening device/tech). That includes ownership rights, transfers of ownership, any licensing deals entered into, distribution deals, joint ventures, equity positions that PGUZ may have received from currently private companies, etc., etc. The reason I would like to see this type of clarification is because Google searches on the company and its technologies leads to a somewhat confusing/conflicting picture.
For example: It appears fairly clear that VE Science Technologies has some involvement in PGUZ's cardiac screening product/technology. I'm not sure whether it is because that company now owns the tech or whether it is from some type of licensing/distribution/marketing deal with PGUZ. In February 2016, VE Science sold the product distribution rights to Odyssey Group International......
http://www.cardiomap.com/
http://theodysseygroupinternational.com/?page_id=65
Despite all the confusion and risks involved, I decided to take a position because if PGUZ does still maintain significant business/financial interests in the above product areas this stock could have some explosive potential based on some of the updates of websites related to the anti-fungal product(s).
To the best of my knowledge, it has never been publicly-disclosed before that large pharma/biotechs like Amgen and Celgene have been using PGUZ's anti-mold product (MoldGuardian)......
OODH(.0025)...accumulated some shares.....
Picked up some shares in case this stock gets a push/promotion in 2017. Recent tweet by the CEO (yesterday) suggests that the Nevada filings will be updated soon, and a corporate update is expected at some point based on the CEO's tweets and the company website......
ECGI...CEO resignation, increased my position.....
I picked up some more shares last week at .0147 following CEO John Bentivoglio's resignation. Not sure if I am throwing good money at a bad situation at this point, but decided to increase my position just in case his resignation marks a bottoming out of the stock somewhere around this 1-2 cent area.
The company has not yet provided investors with any explanation/update as to what is going on. Implications for investors could range anywhere from extremely negative to extremely positive.
I can envision some scenarios here where this change in management of ECGI could turn out to be a favorable move for the shareholders. Gary Blom (from Main Street Capital, an Australian financial services firm) has been appointed Director (and interim CEO?). Blom has a lot of connections in the Australian/Asian markets, and I think his firm has represented the Australian investors/people that have been involved with ECGI (including MedPac Asia Pacific, Julie Singleton, etc.)
Assuming the resignation was not health-related, maybe the change in management is something that the Australian parties have been seeking/requesting.
http://mainstreetcapital.com.au/
VDRM...possible stem cell applications.....
The debt situation and the inability of the CEO to provide a clear/coherent picture of exactly what is occurring with the company obviously makes VDRM an extremely high-risk investment. But from a trading perspective, the stock does have its moments in the sunshine.
The press release this past week was an enouraging sign that additional news/activity may be forthcoming. Although most investor attention was directed toward the marijuana (CBD/THC) aspects of the PR, the fact that VDRM appears to have done some possible rebranding of its antibiotic product is something that caught my eye. According to the drug database, the marketing start date for Viabecline was November 8, 2016......
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3e53ed13-b71e-494d-b292-5b1cac34689f&type=display
Prior to the recent press release, I accumulated some shares of VDRM because I thought the next push/promotion of the stock might involve the stem cell applications of tetracycline. It has gone largely unnoticed by VDRM investors, but over the last 2-3 months Phillips Company (from which VDRM licenses its tech/products) has been placing a PDF file on its website. The file chronicles the use of TetraStem (beginning July 2016) to treat a human spinal cord injury......
http://www.phillipscompany.4t.com/miranda.pdf
GSAC...finished accumulating position....
ECGI(.015)...ambulatory cardiac monitor.....
ECGI is involved in the cardiac monitoring market, and owns the worldwide marketing rights for NowCardio (ambulatory cardiac monitor). NowCardio has received marketing clearance from Health Canada, and the company was planning to file a 510(k) application sometime in late July/August 2016 for marketing in the United States. ECGI acquired National Cardiac Monitoring Center several months ago, and it will basically become the base for ECGI's operations inside the United States.
ECGI had been basing/churning around the 3-5 cent area, but has moved downward recently. I don't know whether this weakness is an indication that some negative news/development might be approaching, or whether it is simply some overhang working its way out of the stock. Possible negative news might involve an unresolved lawsuit, problems with the July acquisition of National Cardiac Monitoring Center, financing, etc., etc.
It might be a high-risk investment until the situation clarifies itself a little better, but these sub-2 cent prices look extremely attractive for entry/accumulation. IMO, absent anything overly negative coming this way, the stock probably should not be trading this low.
If ECGI has filed its 510(k) application for NowCardio according to its last guidance timetable, the company could receive United States marketing clearance for the device as early as the next month or two. I think once ECGI gets the 510(k) approval, you will probably see a significant increase in the amount of US-based media attention on the product/company.
Financings have been done at significantly higher prices. According to the CEO's August audio interview, the most recently announced financing ($300K) was being used to manufacture 1000 NowCardio devices. It is not widely-known by investors, but during the month of August the company placed job postings for CEO and CFO positions for National Cardiac Monitoring Center. Some of the job requirements for the CFO position included investor relations and SEC filings, so I would assume this person would also take over the CFO duties for ECGI.
Another potential sign that operational/marketing activity for NowCardio and ECGI could be taking a step forward is the job posting that Contex International Technologies made in Canada. Contex is the engineering firm that designed the NowCardio device for ECGI. Based on the job posting, it appears that Contex will be setting up a cardiac monitoring center in Canada (essentially a Canadian version of National Cardiac Monitoring Center)......
GSAC(.0035)...cannabis-sector play......
I accumulated shares of GSAC in the .003-.0035 range last week. GSAC acquired ownership of Mastix Medica about two years ago (and in the process gained exposure to the cannabis sector). GSAC is involved in the research/development, formulation, manufacturing, and marketing of over-the-counter healthcare products (gum, tablets, lozenges, mints, candies, etc.). The company has a patent-pending manufacturing process for incorporating hemp-oil into gums and tablets.
Its a very high-risk investment, but the stock looks relatively attractive given its under-followed nature and the current market interest for sub-penny cannabis plays.
Although it is about a year old, the GSAC Executive Summary from November 2015 provides a nice amount of information about the company and its plans it had heading into year 2016. Included in the summary is info on its cannabis-related activity (products, clinical studies, etc.) and some financial/business information regarding potential products in the pipeline.
Also from the summary.....
$hellKing...CLCL(.0078)...accumulated position.....
IVRO(.02)...distribution network now includes India.....
Fiscal year 2015 financial numbers:
22M shares outstanding
$440K market cap
$995K revenue
$232K net income
$650K cash (2.9+ cents per share)
InVitro International develops and manufactures kits and services that are used to test the corrosivity/irritancy of products on ocular/dermal tissues. The company has been in business for decades and appears (based on its two most recent fiscal years) to be at a possible positive turning point in its business activities.
Although IVRO has not yet updated its website to reflect the following, it is interesting to note that IVRO appears to have recently entered into a distribution agreement with a company in India. InVitro's logo and website link can be found on the website of Krishgen Biosystems India. Krishgen has a scrolling news section on the left side of its website. The July 21, 2016 item mentions IVRO and its two products.......
ECGI(.058)...acquisition, medical device clearances.....
ECGI's acquisition of a US-based data monitoring center is expected to occur this Friday (as per the 8-K filing).
In addition to the marketing clearance from Health Canada that the company received for its NowCardio product, ECGI is expecting to receive at least two other marketing clearances before the end of 2016 (United States and Europe).......
CLCL...increased my position....
I accumulated more shares of CLCL this week at the sub-penny level. All things considered, the timing now for entry/accumulation of CLCL probably has never looked more attractive in the years that I have followed the stock.
It is an encouraging sign that both websites CEO Norman Kaplan mentioned in his email to adijas are now offline (see post below). Last week the company took its main website (calcol.com) offline.....
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123541465
ECGI...Health Canada clearance, FDA timeline.....
adijas...CLCL...increased my position.....
Nice financing, corporate development.....
Medical Device Daily...April 19, 2016 article.....
Filing delinquency...reply to private message.....
To the person who sent me a private message regarding VODG's SEC filing delinquency.....
Until VODG actually becomes current on its SEC filings, I think it is only prudent to be at least somewhat concerned about the potential for suspension/revocation of the stock. My guess is that VODG will be able to avoid the SEC taking action on the stock, but that is purely a guess on my part.
Over the last few years the SEC seems to have become increasingly erratic/inconsistent in its approach to handling filing delinquency situations, so anytime you have a stock fall into a delinquent status for an extended period of time (like VODG) it is wise to be somewhat cautious.
That inconsistency by the SEC has made it much more difficult for retail investors in shells and many active/operating small cap companies. There are a number of what I would consider to be extremely attractive shells or operating companies out there, but the SEC's "preemptive strike" policy it enacted a few years ago and its inconsistent/random enforcement of filing deliquencies increases the risk level in these investments.
A few years ago the SEC revoked a perfectly fine 15-12G shell, forcing the attorney who controlled the shell to liquidate the shell and distribute the cash to the shareholders. Meanwhile the SEC allows another shell to continue trading (even though it is now about 24 years delinquent on its SEC filings). I know of one shell a few years ago that was suspended/revoked even though the investment firm that controlled the shell was in fact getting the filings updated. So the firm lost all the money it spent on acquiring the shell, plus any money it spent on the filings. That is the type of inconsistency that has a lot of investors increasingly frustrated.
I think most investors would be served better if the SEC practiced what it preaches: full disclosure. I don't think it is too much to ask that the SEC provide the public with timely information on any contact/demands it has made with any companies it may be targetting for suspension/revocation. It would be incredibly helpful (and potentially very profitable) if you knew whether or not a specific delinquent company or shell was in any significant or imminent danger from the SEC. For example, the delinquent biotech/pharma VPRO had a monster move from its low in the last year or so for those investors who correctly guessed/gambled that the SEC would not suspend/revoke the stock in the near term.
Allowing the average investor an opportunity to make a better buy/sell decision before actually suspending/revoking the stock doesn't seem like an unreasonable request.
Health Canada application, MedPac equity position.....
If the guidance in the quarterly report filed two weeks ago (April 15) is accurate, ECGI should be submitting the NowCardio application to Health Canada sometime within the next two months. Generally speaking, medical device applications in Canada usually get processed quicker than in the United States (weeks/months versus months)......
ECGI...increased my position.....
I increased my ECGI position last week. The risk/reward around this 3-cent area, and the timing for entry/accumulation, looks reasonably interesting right now. I would assume the first of the marketing approvals (Health Canada) is probably getting fairly close. Depending on how much lasting damage was done to the stock during the Fall/Winter, my guess is there will be some potential for pretty nice tradeable moves/spikes in the share price over the next 6-months or so.
Last week, the company (and/or the investors relations firm the company had hired last year) started making some updates to the website. For a better part of the last 6 months or so, the website had basically been neglected. Interesting to note that additions/changes have been made to the management team and the advisory board.......
http://www.eventcardiogroup.com/
The $1.08M financing package (6.4 cents per share, and 15-cent warrants) in February was an important and very encouraging development, especially since the Life Medical dispute has not been resolved yet. It is pretty clear that those investors believe the company will remain a viable business/investment, and it is also an extremely high vote of confidence that ECGI will successfully obtain marketing approvals for NowCardio in markets outside Canada. The way the licensing agreement for NowCardio is currently set up, ECGI only receives significant fundamental benefits from its activity in the non-Canada markets.
Also worth noting (according to the financing agreement 8-K): The company consolidated the bulk of its related party debt into a promissory note convertible at CAN$.0873 (which is usually around 6-7 US cents, depending on currency rates).
March 1 press release is interesting/encouraging.....
dickmilde...regarding IVRO......
IVRO(.0141)...revenue/income/cash at 18-year highs.....
22M shares outstanding
$310K market cap
$650K cash
FY 2015 (September 30) net income around .01/share
Does not file with the SEC or OTC Markets
IVRO develops/markets kits and laboratory services for the testing of ocular and dermal irritancy/toxicity of materials.
The revenue, net income and cash levels reported in IVRO's fiscal year 2015 financial results press release represent 18-year highs for the company.....
GNPG...anticipating corporate developments.....
I'm semi-expecting to see an increase in corporate activity/developments over the next few months. The sale of GNPG's XenTx Lubricants subsidiary could occur sometime in March. Once that is complete I would assume most of the company focus will turn to the remaining subsidiaries.
Over the last month or so, GNPG has made changes to its authorized/preferred share structures, did some slight redesign work on its website, and a new Treasurer/Secretary/Director (Don Burton) was appointed.
It will be interesting to see if any upcoming announcements/developments create some movement/push on the stock in the coming weeks/months.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=120645884
GNPG(.008)...expected sale of a subsidiary....
It has gone largely unnoticed, but in GNPG's February 17 financial results press release the company stated it may announce the sale of its XenTx Lubricants subsidiary sometime in the next 6 weeks. The share price seems to have been firming up a little in the last few weeks, so it is possible this anticipated sale might cause a pop in the share price. GNPG's current fiscal year ends on March 31......
IVRO(.015)...2015 financials, future looks encouraging....
22M shares outstanding
$330K market cap
$995K revenue
$650K cash (2.9+ cents per share)
I picked up some shares of IVRO today. The fiscal year 2015 financial results press release last week shows nice improvements in the areas of revenue, earnings and cash. It is possible this could represent a significant turning point in the company's history, as the CEO's statements in the press release seem upbeat/encouraging......
ASKH(.026)...shell, 11.1M outstanding.....
I'm holding a position in this shell. I think the chances of seeing some type of merger/acquisition activity and/or some type of push/promotion on the stock this calendar year might be relatively decent.
The share structure looks to be reasonably tight right now, with 11.1M outstanding and a float under 3M. The CEO purchased control of the shell in late 2013 and owns 8.16M shares at a cost basis of about 4.3 cents/shr ($350K). Any shares that changed hands during the promotional activity that occurred in the year following his purchase of the shell appears to have come from the existing float, since his share ownership number/percentage has not changed.
During the second half of 2015, ASKH hired a financial/investment consulting firm, registered a new website and regained its SEC filing compliance. That consulting firm is expected to receive about $23K worth of free-trading shares, so I am anticipating there will be a noticeable increase in volume activity at some point.
Primary focus appears to be on acquisition/merger and business activities with companies based in New Zealand and China. The website for the China-based textile company (Jiangsu Ziyang Holiday Bedroom Articles Co. Ltd.) that is currently featured prominently on the ASKH website can be found below. Jiangsu Ziyang appears to have a pretty well-established textile brand. If I recall correctly, the CEO/company was mentioned in a news article last summer and had secured a $2.5 million government loan. The growth plans for 2015-2017 that were put up on company's website back in 2014 included increased expansion into RT-Mart, Carrefour, and Walmart stores.
http://nantongglobalventures.com/
http://www.ziyangjiafang.com/home.html
ECGI...reply to private message.....
To the person who inquired about my current thoughts on ECGI.....
I still hold my position in ECGI, as I think the possibility of substantial upside from this price range still exists. But obviously the risk factor has significantly increased as a result of the disputes between ECGI, Life Medical and Medpac Asia Pacific.
The negative developments surrounding the BreastCare DTS division of the company over the last month or so have been extremely disappointing, to say the least. Unless there is a very reasonable/amicable resolution to all of the disputes here, the entire BreastCare DTS part of the business could end up being an extremely expensive waste of ECGI's corporate time/resources.
In my opinion, most of the current problems/mess could have been avoided if CEO John Bentivoglio and ECGI's legal counsel would have done a better job of protecting the company when the licensing agreement for BreastCare DTS was crafted/signed. At a minimum, there should have been clauses placed in that agreement that would have pushed back the timeline on any financial obligations until after the full-scale production/manufacturing line for BreastCare DTS was actually completed.
The latest 8-K (12/17/2015) about Medpac withdrawing its default notice is a potentially encouraging sign. It would have been helpful if ECGI could have provided a little more clarification on whether the withdrawl means the two parties have completely resolved their particular dispute, or whether the disagreement still exists and Medpac is just temporarily withdrawing its default/demand......